West Pharmaceutical Services, Inc. (WST) Cash Flow Statement

The OCF/NI ratio has been consistently above 1.0 in most quarters, indicating high earnings quality, but the 2026Q1 dip to 0.65x and the 2026Q2 ratio of 0.81x suggest that working capital swings are creating temporary distortions. The large positive working capital change of $102.9M in 2026Q2 versus a negative $102.9M in the prior quarter points to significant timing effects in collections and payables, which investors should monitor for sustainability.

The sequential improvement in FCF margin aligns with the revenue acceleration and margin expansion seen in the income statement, suggesting that the destocking headwind is fading. However, the FCF margin remains below the levels achieved in late 2025, indicating that capital expenditures are absorbing a larger share of operating cash flow as the company invests in capacity for GLP-1 and biologics demand.

The elevated capex intensity, particularly in 2024 quarters (13-14% of revenue), suggests that management is investing heavily in high-value product capacity, likely to meet the accelerating demand for GLP-1 components. The recent moderation to around 5% in 2026 may indicate a pause in major projects, but the absolute dollar amounts remain substantial, and investors should monitor whether these investments translate into sustained revenue growth.

The extreme volatility in working capital changes suggests that customer ordering patterns and inventory management are still adjusting post-pandemic. The positive swing in 2026Q2 may indicate improved collections or reduced inventory build, but the prior quarter's negative swing shows that cash flow can be lumpy. This volatility complicates quarterly comparisons and underscores the importance of focusing on annual trends.

The large buyback in 2026Q2, following a quarter of net issuance, suggests management is confident in the company's cash generation and growth outlook. The consistent dividend payout, though modest, reflects a commitment to returning capital. However, the timing of buybacks appears opportunistic, and investors should monitor whether this pace is sustainable given the elevated capex requirements.

The persistent excess of operating cash flow over net income indicates high earnings quality, with non-cash charges like depreciation and amortization (averaging ~$40M per quarter) providing a cushion. This divergence suggests that reported earnings are backed by real cash generation, reinforcing the strength of the business model. However, the recent quarters show a narrowing gap, which may reflect increased working capital investment.